DLA Piper LLP (US)’s product liability team is a trusted defender of global pharma and medical device companies, having successfully handled numerous high-stakes disputes. It has defended or ended several mass torts through resolution, dispositive preemption, Daubert hearings, and other motions. Leveraging its cross-practice expertise, the team collaborates closely with appellate, regulatory, and life science partners. Atlanta-based Christopher Campbell, co-chair of the product liability group, leads high-profile matters such as Bayer’s global Essure litigation and its phenylephrine cough-cold MDL litigation. Ilana Hope Eisenstein, chair of US litigation based in Philadelphia, specializes in complex issues, developing and managing legal strategy. In New York, Loren Brown chairs the wider US disputes practice and leads the firm’s representation of Novo Nordisk as national trial counsel in litigation related to diabetes and obesity medications Ozempic, Wegovy, and Rybelsu. Boston-based Matthew Holian is another key figure in the practice, frequently serving as national counsel in complex, multi-jurisdictional matters. ‘Client-focused’ Katie Insogna, also in Boston, is ’outstanding at managing the intricacies of a day-to-day high-stakes mass tort’, while New York’s Lucas Przymusinski leverages his medical background to drive legal strategy. Meanwhile, Steve Huffaker, who joined the Austin office from King & Spalding LLP in September 2024, focuses on mass tort coordination and strategy, early case resolution, group settlements, litigation risk strategy, and fact and expert witness development and discovery.
Legal 500 redaktioneller Kommentar
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘In my experience, one of the best practices I have worked with in over 2 decades of experience - the level of responsiveness, breadth of expertise, industry and technical knowledge, and pragmatic approach is unmatched.’
‘DLA Piper LLP (US) is doing a fantastic job in global strategy for cross-country litigation.’
‘The team focuses on the client's expectations and preferences. Their strengths are strategy, providing concrete legal advice, coordination skills, and reliability to get things done. They integrate/cooperate well with legal teams from other law firms to achieve the overall goal rather than being competitive.’
‘The team is very responsive and thorough. They quickly understand the issues. The advice is practical and proportionate to the risk.’
‘I would particularly like to stress the work that Chris Campbell is doing. He gives precise advice as required, he always thinks in the best interest of his clients and always thinks ahead. He will think through the most complex issues very fast, taking all relevant facts into consideration. This always leads to the best advice. Mary Gately is fantastic in analyzing complex medical issues and their impact on the litigation strategy.’
‘Loren Brown has tremendous credibility with Judges and opposing counsel. He is terrific at managing a mass tort. Lucas Przymusinski is an MD/JD who leverages his medical background to drive medical/legal strategy. Katie Insogna is client-focused and does an outstanding job of managing all the intricacies of a day-to-day high-stakes mass tort.’
‘Lucas Przymusinski, Katie Insogna and Ray Lewis have exceptional responsiveness, a pragmatic approach, and breadth of knowledge of industry combined with medical expertise, yet are all humble and approachable.’
‘Lucas Przymusinski very quickly understands the science so he can provide an important risk perspective. I'm continually impressed by the speed and rigor with which he does his analysis.’
Kernmandanten
- 3M Company, The
- BASF Corporation
- Novo Nordisk A/S
- Bayer Corporation
- Danone
- Exxon Mobil Corporation
- Medtronic, Inc.
- Pfizer
- Sanofi
- Johnson & Johnson
Highlight-Mandate
- Representing Novo Nordisk regarding litigation and regulatory issues related to its diabetes and obesity medications Ozempic, Wegovy, and Rybelsus.
- Representing Sanofi for litigation and regulatory issues relating to Zantac, a common heartburn medication that allegedly contains and/or is contaminated with NDMA, a possible carcinogen.
- Representing Bayer in proceedings relating to Essure, a permanently implantable contraceptive device for women that Bayer voluntarily discontinued in 2018.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Praxisleitung
Christopher Campbell; Ilana Hope Eisenstein; Loren Brown
Weitere Kernanwält*innen
Matthew Holian; Katie Insogna; Lucas Przymusinski; Mary Gately; Jessica Wilson; Steve Huffaker